At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Direct Lentiviral TYF-ARSA Injection Gene Therapy for Metachromatic Leukodystrophy (MLD)
In Brief
A clinical study evaluating Intrathecal and intravenous LV gene therapy for Metachromatic Leukodystrophy (MLD). Currently recruiting, targeting 10 participants across 1 site.
Detailed Summary
This is a Phase I/II clinical trial of gene therapy for treating Metachromatic leukodystrophy (MLD) using a safety and efficacy improved self-inactivating lentiviral vector TYF-ARSA to functionally correct the genetic defect. The primary objectives are to evaluate the safety and efficacy of the direct gene transfer clinical protocol.
Study Details
Timeline
Arms & Interventions
Intrathecal and intravenous injections with lentiviral TYF-ARSA vector carrying the functional gene
Interventions
Direct IT and IV LV gene therapy to deliver high levels of LVs at 1-2×10\^9 transduction units/ml which carry a normal ARSA gene